Literature DB >> 25370709

The effects of bisphosphonate on the remodeling of different irregular bones in mice.

Jiansheng Su1, Mu Feng1, Wenfei Han1, Hang Zhao1.   

Abstract

BACKGROUND: We aimed to compare the effects of bisphosphonate on the remodeling of irregular bones (the jaw and ilium) in mice after trauma.
METHODS: To verify the feasibility of modeling osteonecrosis, 20 mice were injected intraperitoneally with zoledronate and dexamethasone (ZOL&DEX group), dexamethasone (DEX group), or phosphate-buffered saline (PBS) [control (CTR) group]. Mice then underwent extraction of the right maxillary first molar and creation of an artificial bony cavity in the ilium. Bone sections were stained with H&E for morphological studies. To further compare differences between the maxilla and the ilium caused by similar traumas, 80 mice were injected intraperitoneally with ZOL&DEX or PBS. Pathological progression at the injury sites was assessed at 1 day and at 1, 3, and 8 weeks after trauma using micro-computed tomography (CT), H&E and immunohistochemistry analyses, high-performance liquid chromatography-mass spectrometry, and enzyme-linked immunosorbent assay.
RESULTS: Only the ZOL&DEX model group effectively developed osteonecrosis. Bony sequestra, osseous sclerosis, unhealed mucosa, and radiopaque alveolar bone were found in the maxilla. In the ilium, there was a lower frequency of osteonecrotic disease and osseous sclerosis, and less suppression of bone remodeling than in the maxilla following long-term bisphosphonate administration. Zoledronate levels were higher in the maxilla. ZOL&DEX treatment suppressed the levels of RANKL and IL-17, but induced an upregulation of osteoprotegerin and FAM20C in both bones.
CONCLUSION: Accumulation of bisphosphonate may increase the incidence of osteonecrosis. The RANKL/OPG pathway and IL-17 and FAM20C cytokines play key roles in the progression of pathologically abnormal bone remodeling.
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  bisphosphonate-related osteonecrosis of the jaw; bisphosphonates; bone remodeling; osteonecrosis; pathogenesis

Mesh:

Substances:

Year:  2014        PMID: 25370709     DOI: 10.1111/jop.12281

Source DB:  PubMed          Journal:  J Oral Pathol Med        ISSN: 0904-2512            Impact factor:   4.253


  8 in total

1.  Role of osteoclasts in oral homeostasis and jawbone diseases.

Authors:  Maiko Omi; Yuji Mishina
Journal:  Oral Sci Int       Date:  2020-07-21

Review 2.  Current Understanding of the Pathophysiology of Osteonecrosis of the Jaw.

Authors:  J Chang; A E Hakam; L K McCauley
Journal:  Curr Osteoporos Rep       Date:  2018-10       Impact factor: 5.096

3.  Small Extracellular Vesicles Derived from Adipose Tissue Prevent Bisphosphonate-Related Osteonecrosis of the Jaw by Promoting Angiogenesis.

Authors:  Jiao Huang; Lin Wang; Weidong Tian
Journal:  Int J Nanomedicine       Date:  2021-05-07

Review 4.  Preclinical models of medication-related osteonecrosis of the jaw (MRONJ).

Authors:  J I Aguirre; E J Castillo; D B Kimmel
Journal:  Bone       Date:  2021-09-11       Impact factor: 4.398

5.  Effect of bisphosphonates on the mandibular bone and gingival epithelium of rats without tooth extraction.

Authors:  Francesco Saverio DE Ponte; Luciano Catalfamo; Gregorio Micali; Michele Runci; Giuseppina Cutroneo; Giovanna Vermiglio; Antonio Centofanti; Giuseppina Rizzo
Journal:  Exp Ther Med       Date:  2016-03-15       Impact factor: 2.447

Review 6.  Pathogenesis of medication-related osteonecrosis of the jaw: a comparative study of in vivo and in vitro trials.

Authors:  Henrik Holtmann; Julian Lommen; Norbert R Kübler; Christoph Sproll; Majeed Rana; Patrick Karschuck; Rita Depprich
Journal:  J Int Med Res       Date:  2018-08-09       Impact factor: 1.671

7.  Medication-related osteonecrosis of the jaws after tooth extraction in senescent female mice treated with zoledronic acid: Microtomographic, histological and immunohistochemical characterization.

Authors:  Claudia Cristina Biguetti; André Hergesel De Oliva; Kent Healy; Ramez Hassan Mahmoud; Isabela Do Carmo Custódio; Dulce Helena Constantino; Edilson Ervolino; Marco Antonio Hungaro Duarte; Walid D Fakhouri; Mariza Akemi Matsumoto
Journal:  PLoS One       Date:  2019-06-14       Impact factor: 3.240

8.  Bevacizumab and sunitinib mediate osteogenic and pro-inflammatory molecular changes in primary human alveolar osteoblasts in vitro.

Authors:  Elena Hofmann; Benedikt Eggers; Marjan Nokhbehsaim; Werner Götz; Nils Heim; Franz-Josef Kramer
Journal:  Odontology       Date:  2022-02-16       Impact factor: 2.885

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.